Abstract
Ataxia-telangiectasia (A-T) is an ultrarare autosomal recessive disorder and occurs in all racial and ethnic backgrounds. Clinically, children and young people with A-T are affected by sinopulmonary infections, neurological deterioration with concomitant bulbar dysfunction, increased sensitivity to ionizing radiation, immunodeficiency, a decline in lung function, chronic liver disease, endocrine abnormalities, cutaneous and deep-organ granulomatosis, and early death. Pulmonary complications become more frequent in the second decade of life and are a leading cause of death in individuals with A-T. Oropharyngeal dysphagia is common, progressive, and a risk factor for frequent respiratory infections. Immunodeficiency is non-progressive in most patients with A-T. If severe infections occur, one should be aware of other possible causes, such as aspiration. We provide an overview of current best practice recommendations, which are based on combinations of extrapolation from other diseases and expert opinion. These include proactive surveillance, monitoring, and early management to improve lung health in this devastating multisystem disease.
Introduction
Ataxia-telangiectasia (A-T) is an ultrarare autosomal recessive disorder caused by mutations in the Ataxia-telangiectasia mutated (ATM) gene, located on the long arm (q) of chromosome 11 (11q22–23). A-T affects between 1 in 40,000–300,000 live births worldwide (1) The Orphanet registry estimates the average prevalence of A-T at 1/100,000 children (2). The most reliable estimates for the number of people with A-T, in the UK at least, are 3 per million (3), and hence individual clinicians are likely to have limited experience in treating the disease. A-T occurs in patients of all racial and ethnic backgrounds and is associated with premature death in most people afflicted with the disease. The ATM protein is a 350 kDa serine/threonine protein kinase that is essential for double-stranded DNA repair following double-stranded DNA breaks (DSBs). ATM is also a critical constituent of the DNA damage response (DDR) pathway and is involved in detecting elevated oxidative stress and responding to DNA damage that occurs from the production of reactive oxygen and nitrogen species (RONS) by playing a critical role in the cellular antioxidant response to elevated oxidative stress and inflammation (4). In the absence of the ATM protein, the DDR response is compromised and cellular damage from oxidative stress may be amplified (5). DSBs can occur following exposure to ionizing radiation and this has implications for the use of diagnostic methods but, more importantly, for the use of therapeutic radiation in people with A-T. Double-stranded DNA breaks also occur during V(D)J-recombination, which is integral to the adaptive immune response. V(D) J-recombination is the process by which antigen receptors are assembled using distinct variable (V), diversity (D), and joining (J) gene segments as building blocks for T-cell receptor immunoglobulin chains (6). V(D)J-recombination is thus required for the expansion of the antibody and T-cell receptor repertoire response to foreign pathogens. Classically, V(D)J-recombination defects result in severe combined immune deficiency (SCID) with a lack of T and B lymphocytes (7). However, because there are functional redundancies in V(D)J-recombination, a total absence of ATM does not usually cause the severe immunodeficiency phenotype found in individuals with SCID. A positive result on newborn screening for SCID that is subsequently found not to be due to SCID should lead to additional testing and the diagnosis of A-T can be made after genetic studies are performed. This is because some infants with A-T have sufficiently low circulating copy numbers of T-cell receptor excision circles (TRECs) to trigger an abnormal report in the assay that detects SCID. In the UK, a handful of children are diagnosed annually with A-T after newborn screening.
The clinical and laboratory immunodeficiency markers in A-T varies between patients and can change during life. In approximately 70% of patients with classical A-T, ATM deficiency results in primary immune deficiency (PID) with highly variable features. Most patients have humoral and cellular immune defects comprising immunoglobulin-A (IgA) deficiency, immunoglobulin-G2 (IgG2) and immunoglobulin-G deficiency (IgG), and lymphopenia with low numbers of total and naïve CD4 T cells. Truncating mutations that result in a total absence of ATM kinase activity (null mutations) are present in severely affected patients, while at least one missense or splice site mutation is present in patients with milder phenotypes, resulting in the expression of ATM with some kinase activity (8, 9).
Between 10% and 60% of patients with A-T exhibit the hyper-immunoglobulin M (IgM) phenotype, with low IgG and IgA but with normal or elevated IgM (10–17). Patients with the hyper-IgM phenotype have worse overall survival, but the presence of IgG2 or IgA deficiency does not influence survival in A-T (18). Normal to high IgM levels are present as these individuals cannot switch from the production of IgM to other immunoglobulin classes due in part to the abnormal class switch recombination process (18).
Immunodeficiency is non-progressive in most patients with A-T. If severe infections occur, one should be aware of other possible causes, such as aspiration (8, 19–23).
Clinically, people with A-T are affected by sinopulmonary infections, neurological deterioration with concomitant bulbar dysfunction, increased sensitivity to ionizing radiation, immunodeficiency, a decline in lung function, chronic liver disease, endocrine abnormalities, cutaneous and deep-organ granulomatosis, and early death (17, 24–27). Pulmonary complications become more frequent in the second decade of life and are a leading cause of death in individuals with A-T. Oropharyngeal dysphagia is common, progressive, and a risk factor for frequent respiratory infections.
Given the myriad of system involvement in A-T and the rarity of the condition, delayed diagnosis is not uncommon (28) and clinicians should consider requesting an alpha-fetoprotein level test and confirming the genetic diagnosis when faced with a child with suggestive symptoms and signs (Box 1).
Box 1 When to consider and confirm a diagnosis of A-T.
- 1.
Positive newborn screening test for inborn error of immunity which is not due to SCID.
- 2.
Combination of lymphopenia and hypogammaglobulinemia.
- 3.
Sibling with a confirmed diagnosis of A-T.
- 4.
Investigating a toddler with ataxia, which is progressive, or “clumsiness,” which is atypical or more noticeable as compared to their peers.
Neurological manifestations contribute to respiratory disease (24, 25). A detailed description can be found elsewhere (24), but Table 1 [adapted from van Os et al. and Petley et al. (24, 29)] summarizes the key manifestations.
Table 1
| Classical A-T | Time frame of onset in classical A-T | A-T variant | |
|---|---|---|---|
| Cerebellar ataxia, wide-based walking (gait ataxia), nystagmus, dysarthria, dysphagia, wobbling of the head and trunk (titubation), and shakiness when reaching (dysmetria) | Early and progressive | Generally presents at 12–18 months of age | Mild or absent |
| Extrapyramidal movement disorders (dystonia and tremor) | Later and less common | Between 4 and 6 years of age | Common feature |
| Oculomotor apraxia and nystagmus | Later and less common | Between 2 and 7 years of age | Common feature |
| Polyneuropathy and motor neuron disease | Later and less common | Second decade of life | |
| Cognitive impairment | Not a dominant feature | Not studied |
Neurological manifestations of A-T.
The respiratory manifestations (
Table 2) of A-T are:
- (a)
acute and chronic respiratory tract infection, with the risk of bronchiectasis, which is multifactorial. Risk factors include immune deficiency, aspiration due to uncoordinated swallowing, and impaired secretion clearance due to respiratory muscle dysfunction. Bronchiectasis can develop even before 3 years of age (30). Frequent sinopulmonary infections in A-T have been reported since early case reports were published (31), even before the underlying genetic basis of the disease was recognized, and is a very well-recognized component of the A-T syndrome. Pleural effusion is uncommon and should lead to a search for infective (32) and non-infective etiology including malignancy (33, 34);
- (b)
aspiration syndromes, related to uncoordinated swallowing and abnormal head posturing, can lead to/worsen bronchiectasis (see below);
- (c)
scoliosis, especially in adolescence;
- (d)
in adolescence, some people with A-T are wheelchair-bound and develop decreased physical conditioning with subsequent shallow breathing and reduction of tidal volume and inability to completely exhale further aggravating restrictive lung disease;
- (e)
(much more rarely) interstitial lung disease (ILD)/pulmonary fibrosis;
- (f)
restrictive and obstructive lung disease may develop after chemotherapy for malignancy.
Table 2
| Underlying problem | Respiratory consequences | Time frame of onset |
|---|---|---|
| Immune deficiency (due to underlying disease or secondary to treatment of a malignancy) | Recurrent upper and lower airway infections. Bronchiectasis with a “vicious cycle” of infection, inflammation, and secondary impairment of mucociliary clearance. Potential lower airway contamination from upper airway infection. | In preschool years, this may be difficult to distinguish from the recurrent infections seen in normal children Bronchiectasis: The youngest age at which bronchiectasis was diagnosed was <3 years. The oldest child reported with no bronchiectasis was 108.0 months. |
| Bulbar dysfunction | Recurrent lower airway infection and bronchiectasis. Inefficient cough due to failure of coordinated glottal closure. | Later in the first decade to early second decade. |
| Abnormal chest wall/scoliosis | Respiratory muscle dysfunction. Respiratory failure, initially nocturnal then daytime also. | Late teens |
| Inspiratory muscle dysfunction | Atelectasis Weak cough Respiratory failure, initially nocturnal then daytime also. | Later in the first decade to early second decade. |
| Expiratory muscle dysfunction | Weak cough | Later in the first decade to early second decade. |
| Unknown | Interstitial lung disease | Late teens |
| Malnutrition | Increased susceptibility to infection. Respiratory muscle weakness. | Later in the first decade to early second decade. |
| Physical deconditioning due to reduced activity and ataxia | Impaired secretion clearance Atelectasis. | Later in the first decade to early second decade. |
| Iatrogenic | Toxicity of anti-cancer chemotherapy, radiotherapy, and other treatments such as corticosteroids. | Later in the first decade to early second decade. |
Respiratory manifestations of A-T.
Patterns of respiratory care
There are no large adequately powered randomized controlled trials of any respiratory treatments in A-T so all recommendations are based on combinations of extrapolation from other diseases and expert opinion (25).
We have updated the 2015 European Respiratory Society statement on multidisciplinary respiratory management of A-T (25) with additional material that has been published subsequently (Box 2).
Box 2 New research and information related to A-T since 2015.
- •
Two further reviews on multidisciplinary management of ataxia-telangiectasia.
- •
A systematic review of the natural history of A-T.
- •
Recognition of new presentations of lung disease in A-T, for example, chylothorax.
- •
Use of new modalities for respiratory monitoring, such as sniff nasal inspiratory pressure and peak cough flow.
- •
Update on immune responses and recommendations on immunization.
- •
New management strategies for pulmonary disease including nebulized saline, anesthetic challenges, and oxygen usage during critical care.
Given the complexity of the respiratory complications of A-T, it is strongly recommended that all children are cared for by a respiratory pediatrician in a local tertiary regional center (25). In suitable circumstances, a shared care system may be operated with a local district general hospital, similar to the cystic fibrosis (CF) model. There are similarities (progressive lung disease, respiratory microbiology, and multisystem involvement such as liver disease and diabetes) and differences [multiple contributors and phenotypes of lung disease (see Table 2), progressive neurological disease, risk of different types of cancers, and radiation susceptibility] between A-T and CF. As in CF, monitoring and treating respiratory infections (even in the era of highly effective modulatory therapy for CF), multisystem A-T-specific health issues, such as diabetes, liver disease, neurological disease, cancers, and psychosocial issues require multidisciplinary care with input from the relevant specialists. It is considered good practice that, as with CF (35, 36), there is an annual review undertaken so as to have proactive surveillance and early detection of any complication arising from A-T. In a shared care, non-specialist center, this should be undertaken by the responsible lead clinician with guidance from the specialist center. In addition, we recommend that these patients have a respiratory review at least every 3 months and more frequently if the child is unstable.
Best practice recommendations for infection control, including hand hygiene, contact precautions, regular microbiological surveillance, and segregation in clinical and social settings to minimize the acquisition of common pathogens, should be followed.
The components of the review should include (
25) the following:
- •
Assessment by an experienced pediatrician.
- •
Assessment of airway clearance techniques by a physiotherapist with a special respiratory interest.
- •
Assessments by a speech and language therapist, and dietetic review to ensure optimal nutrition, are essential.
- •
Culture of sputum or cough swab including for Pseudomonas aeruginosa.
- •
Availability of pulmonary function tests for those children able to perform the technique. The underlying neurological involvement can make it difficult to obtain reliable reproducible dynamic lung function tests that require effort, active cooperation, and coordination. Specifically, children with A-T may struggle to attain full inflation (inspiratory muscle dysfunction) and full expiration (expiratory muscle dysfunction). People with A-T who have late glottis closure will produce forced vital capacity (FVC), slow vital capacity (SVC), and total lung capacity (TLC) results that are underestimated, and lead to the forced expiratory volume in 1 second (FEV1)/FVC and residual volume (RV)/TLC being overestimated, in addition to an overestimated VA. Inspiratory muscle weakness also leads to underestimates of TLC and mean inspiratory flow (VI)/tidal volume (VT). However, several researchers have demonstrated that pulmonary function testing with certain modifications can be performed reliably and be reproduced in patients with A-T and these tests may be used to track the rate of decline in lung function over time (20, 37–40). The reproducibility of standard spirometry testing is increased by stabilizing the patient's head, holding their cheeks while the patient performs the forced expiratory maneuver, optimizing the fit of the mouthpiece, and assessing for leaks in the system. Thus, the majority of adolescents with A-T are then able to perform spirometry testing with minimal modifications. Flow–volume curves do meet recommended American Thoracic Society (ATS)/European Respiratory Society (ERS) reproducibility criteria but often fail to meet other standard recommendations for forced spirometry and will often underestimate respiratory function. Impulse oscillometry and the forced oscillation technique require minimal patient cooperation and are especially useful in those who cannot perform effort-dependent exhalation (41, 42). These techniques can be used to assess small or large airway obstruction, bronchodilator responsiveness, or response to bronchoprovocation. Such investigations are increasingly being used in children in clinical settings (41) for asthma, bronchopulmonary dysplasia, CF, and more recently in ILD (43–45). As such testing is becoming much more available, there are standard technical recommendations (46). Impulse osciliometry (IOS) has the potential to become a useful modality of lung function in people with A-T. Multiple breath washout is also being increasingly used to detect lung disease in patients with inborn errors of immunity (IEIs), including A-T and is more sensitive than spirometry (47). Despite the technical issues, there are now physiological tests to track changes over time, even in A-T patients who cannot perform standard pulmonary function test (PFT). The use of tracking peak flow and force expiratory time, in addition to peak cough flow may also be of clinical adjunct in following expiratory weakness and fatigue.
- •
Stringent follow-up lung function monitoring should be adhered to in survivors of cancer. Elevated serum levels of IL-6 and IL-8 in people with A-T have also been associated with an increased risk of malignancies and worse lung function in people with A-T (48, 49).
- •
Pulse oximetry: Spot checks at routine surveillance clinical visits should be conducted using overnight saturation studies if there are any concerns regarding disordered breathing during sleep, worsening bronchiectasis, pulmonary aspiration (50), or suspicion of intestinal lung disease.
- •
Specialist radiology: DSBs can occur following exposure to ionizing radiation. For this reason, the need for x-rays should be carefully considered and be undertaken only if radiographic imaging is clinically needed to direct therapy. Thus, chest x-rays and computed tomography may occasionally be justifiable despite the increased radiosensitivity; however, the dose of radiation must be minimized under the supervision of an experienced pediatric radiologist. Having said this, the cardinal error of using such low-dose radiation that the images are uninterpretable must be avoided. Application of ionizing radiation-free imaging techniques for the assessment of the respiratory tract, including lung ultrasound (US) and lung magnetic resonance imaging (MRI) have a potential role in the assessment and monitoring of lung disease related to A-T. The lung US (51) can show changes such as multiple subpleural consolidations and B line artifacts related to the interstitial-alveolar syndrome and pleural effusion. Lung MRI (52) can detect mediastinum lymphadenopathy, bronchiectasis, peribronchial thickening, mucous plugging, and collapse/consolidation. In one study, total MRI score was higher in patients with respiratory symptoms, but abnormalities were present in all patients although only 53% had recurrent/chronic respiratory symptoms. MRI scores from patients with positive or negative sputum cultures were not significantly different. MRI has also been emerging as an imaging modality to assess ILD (53). MRI does hold promise as a modality that can be used on an annual basis to monitor lung health, detect any pulmonary changes, and monitor the effects of any treatment interventions. According to expert guidelines (5, 24, 25), imaging should be accompanied by regular lung function monitoring aimed at the early detection of lung disease progression and the need for therapeutic interventions. Ongoing studies (54) may inform us in the future about the age from which to start doing annual lung MRI scans, and the specific scanning sequences and functional techniques to monitor changes over time.
- •
It is assumed that the child will have access to all basic forms of support, including pediatric psychology, occupational therapy, social work, and play therapy, and all relevant professionals to ensure optimal access to services including school. The UK A-T service model is an innovative three-way partnership between national centers of expertise, local care teams, and patient organizations. The model provides a workable approach to address some of the logistic challenges that the patients and families encounter in this rare, complex, and life-limiting condition (55).
Management of respiratory disease
This has been extensively reviewed in the ERS statement (25). The key points are as follows:
Preventative measures to promote lung health
Preventative measures to promote lung health are essential and include avoidance of first- or second-hand cigarette smoke and electronic cigarette vapor exposure and full immunizations, including annual influenza and COVID-19 immunizations (see below). Inactivated vaccines are safe in ataxia-telangiectasia and are recommended as part of routine childhood vaccination programs, except for patients who are on immunoglobulin replacement therapy. Unless the diagnosis of A-T is made early, based on family history or by newborn screening, these children would have received live vaccination inadvertently, e.g., magnetic resonance imaging (MMR) or bacillus calmette-guérin (BCG). Clinical experience has been reassuring and adverse reactions to live vaccinations have not been described. However, as a general principle, live vaccinations, including the live attenuated influenza vaccine, should not be given to children or adolescents with A-T who are clinically severely immunocompromised.
Annual vaccination with an inactivated influenza vaccine is recommended for all patients, including those receiving immunoglobulin replacement therapy (56). However, experimental work shows that in mice, Atm is required to mount a proper memory response against the influenza virus by producing neutralizing virus-specific antibodies, T-cell memory, and resolution of inflammation following primary influenza virus infection. This implies that vaccination of children with A-T by itself may insufficiently protect against respiratory viral infections (57). Several studies have found a diminished response to pneumococcal vaccination. Expert guidelines recommend vaccination of all patients with ataxia-telangiectasia with a 13-valent pneumococcal conjugate vaccine followed by a 23-valent pneumococcal polysaccharide vaccine, repeated every 5 years (24, 25).
A-T and COVID-19
It is now very well-recognized that COVID-19 is associated with milder disease in children compared to adults. Even during the peak of the COVID-19 pandemic, studies (58–60) showed that pre-existing respiratory, immunological, or neurological disease in children (deemed clinically extremely vulnerable risk groups) did not appear to be a significant risk factor for severe COVID-19. Moeller et al. (60) reported that 284 out of 945 (30%) children required admission to hospital including 35 (4%) who were treated in PICU, only one of whom was a child with A-T. Out of the 247 A-T patients on the Iranian national registry, 36 patients (14.5%) had a confirmed COVID-19 infection. Of these, 35 were asymptomatic or showed mild symptoms. Only one child with both autosomal recessive A-T and X-linked recessive Toll-like receptor 7 deficiency required admission to a critical care unit (58).
COVID-19 immunization
None of the COVID-19 vaccines contain live virus. Children and young people (CYP) with A-T should receive a COVID-19 vaccine whether or not they previously had a COVID-19 infection, and whether or not they are receiving immunoglobulin replacement therapy. During the height of the pandemic, some specialist A-T centers suggested that a blood test for the level of the anti-COVID-19 antibody be performed 4–6 weeks after the second dose of vaccine to confirm protective antibody levels (61).
The recommendations in autumn 2024 (62) in the UK were that a booster dose should be given to individuals aged 6 months and over in a clinical risk group which includes anyone with chronic respiratory, neurological disease, or immunosuppression. Hence all individuals with A-T should be offered the vaccine.
Infection
Routine microbiological surveillance should be undertaken and additional samples obtained at the time of change in symptoms from the stable baseline. A-T lung disease has been associated with both bacterial and viral infections, but usually not opportunistic pathogens (19, 21, 22, 63). Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae, Staphylococcus aureus, and occasionally Pseudomonas species are the main pathogens in culture-positive patients (25). There is evidence of dysbiosis of the upper airway in these patients and increased numbers of S. pneumoniae (64). Yeo et al. reported that nasal epithelial cells from individuals with A-T were more sensitive to the damaging effects of infection with S. pneumoniae than controls and that this was partially due to the production of H2O2 by S. pneumoniae (64). Patients with A-T with elevated IgM levels (as compared to those with normal IgM levels) are more prone to chronic infection of the lower respiratory tract with pathogenic gram-negative bacteria P. aeruginosa, fungi, and non-tuberculous mycobacteria (NTM) (16). In these patients, respiratory infections manifest at a very young age and they have a more severe phenotype, as they are more likely to have autoimmune disease, more likely to be receiving immunoglobulin replacement therapy, and show decreased survival compared to patients with A-T with normal IgM levels (10–17).
Respiratory viruses
In a prospective case-controlled study where symptom questionnaires and nasopharyngeal swabs for respiratory viruses were obtained monthly, CYP with A-T were more frequently symptomatic in comparison with controls whether or not a respiratory virus was detected on routine microbiological surveillance (65).
Antibiotic treatment should be considered under the following circumstances:
- •
Any increase in respiratory symptoms, especially chronic wet cough, irrespective of whether there are any abnormalities heard with the stethoscope. A culture of respiratory secretions should be performed and airway clearance techniques be reviewed. Blind treatment with oral antibiotics should be commenced, guided by previous cultures. If there are no previous helpful results, then blind treatment with co-amoxiclav or another antibiotic which covers H. influenzae, M. catarrhalis, S. pneumoniae, and S. aureus should be given. We recommend the use of high doses (formerly a “serious infection” dose) for 2–4 weeks, continuing until the child has returned to baseline for at least 7 days or when the family feels that the child is more or less returned to baseline. Antibiotics can be changed depending on the culture results.
- •
Any positive upper or lower airway culture, especially for bacteria commonly cultured in people with A-T (H. influenzae, S. pneumoniae, and P. aeruginosa) (22) should be treated with 2–4 weeks of an appropriate oral antibiotic as above, even if the child is asymptomatic. It is known that there is an increased susceptibility of airway epithelial cells to S. pneumoniae infection in ataxia-telangiectasia (64). In addition, patients with primary antibody deficiency have a significant respiratory symptom burden associated with increased viral infection and a more frequent presence of H. influenzae and S. pneumoniae in the upper respiratory swabs despite immunoglobulin replacement and prophylactic antibiotic use (66). However, it has been shown that positive upper airway cultures bear no relation to lower airway cultures, inflammation, or structural lung damage in the lungs at the time that the cultures are taken or 1 year later in children with CF (67). Although the relationship between upper and lower airway cultures has not been studied in A-T, and despite the weak relationship in other diseases, our (non-evidence-based) practice would be to treat a positive upper airway culture. Whether a greater use of induced sputum, as in CF (68), would improve outcomes is a matter for future research.
- •
If the response to oral antibiotics is inadequate, or the child is very unwell, then admission for intravenous antibiotics and intensive airway clearance is mandated. The choice of intravenous antibiotics will depend on cultures or a best guess. The isolation of P. aeruginosa should be treated with a CF-protocol eradication regime (69), for example, 3 weeks of oral ciprofloxacin and 3 months of nebulized colistin.
- •
In a child with a chronic productive cough despite trials of antibiotics, especially if they are culture-negative, consideration should be given to an induced sputum sample or fiberoptic bronchoscopy (FOB) and bronchoalveolar lavage (BAL) to obtain material for culture. Opportunistic infections are rare in A-T, but if suspected, early FOB and BAL are mandated.
- •
Children with A-T are also prone to sinusitis and otitis media, and these should also be treated with prolonged courses of antibiotics. In those patients with frequent exacerbations or who are refractory to treatment, specialist referral for sinonasal MRI, nasoendoscopy, and sinoscopy will help guide and optimize treatment. Sinus CT should be avoided if possible, because of the radiosensitivity which is intrinsic to A-T.
Long-term maintenance antibiotic treatment is considered on an individual basis when the burden of respiratory infections is high, but microbiological resistance and side-effects should be always borne in mind. When indicated, azithromycin is commonly used, an extrapolation from other primary immunodeficiency disorders (
70). Azithromycin may already have been commenced by the treating immunologist.
Immunoglobulin replacement
Immunoglobulin replacement therapy is indicated in all patients with a severe immunoglobulin-G deficiency (serum immunoglobulin-G < 4 g/L) and in those with a high IgM phenotype (19, 71); it should also be considered for patients with milder humoral immune defects, recurrent infections, or low specific antibody responses despite booster immunization (56). However, published studies report a wide variation in practice with between 13% and 60% of patients with A-T receiving replacement immunoglobulin therapy (25).
Respiratory physiotherapy
Measures to improve airway clearance and prevent atelectasis are likely to be beneficial in patients with A-T, especially in those with more advanced neurological decline, as they have both impaired secondary mucociliary and cough clearance (25). Although not specifically studied in A-T, it is well known that pollutants, common bacterial pathogens, and respiratory viruses can affect normal ciliary function. A number of mechanisms may underlie this, including the production of specific ciliotoxins, which impair ciliary motion and coordination, disrupt the microtubule function of ciliated columnar cells, and change the viscosity of airway mucus. Furthermore, inflammatory cytokines in the presence of infection can also negatively modulate cilia function (72). As in other neuromuscular disease disorders, treatment regimens may be intensified during episodes of acute illness. Physiotherapy advice regarding which techniques to adopt to optimize airway clearance before irreversible structural lung damage occurs is desirable, although there is no firm evidence base to give specific advice for patients with A-T. There has been only one longitudinal study (73) that assessed spirometry, subjective sensation of dyspnea, maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP), and quality of life (QoL) before and after a 24-week inspiratory muscle training program in 11 patients with A-T and nine healthy volunteers. The results showed that inspiratory muscle training was effective in improving ventilatory pattern, lung volume, respiratory muscle strength, and the health and vitality domains of quality of life in patients with A-T. Inspiratory muscle training was an effective adjunct therapy to drug treatment for patients with A-T. A recent scoping review on multidisciplinary team (MDT) care in five non-research sources of evidence found that common recommendations included improving pulmonary function and reducing aspiration within a multidisciplinary approach (24, 25, 74–76) with an emphasis on regular activities and breathing exercises for optimizing respiratory function. Hence, it would be considered good practice to advise some form of regular exercise, even in younger children who are still mobile and not yet on a downward trajectory of pulmonary and neurological decline. Physical therapy and exercise should not be used to the point of fatigue. Children and adolescents with A-T often complain of progressive daily fatigue which can be exacerbated by physical activities. The etiology of the fatigue is not completely understood but its presence and severity may be associated with progressive neurological deterioration. Other causes of fatigue can include disruption or fragmentation of nighttime sleep, poor nutrition, depression, or other medical causes (5). A range of interventions (and suggestions to reduce the potential for tripping and falling and avoid injuries) that positively impact ataxia-related impairments, activity, or participation levels, together with QoL measures, have been very well summarized in a recent review (77).
There are no studies into the efficacy of nebulized hypertonic saline, rhDNase, or inhaled mannitol on the mobilization of mucus in A-T. The prescription of nebulized saline in CYP with neurodisabilities with a median age of 11 years (none with A-T) was associated with improved respiratory outcomes in a retrospective study (a decrease in the number of hospitalizations per year and a decrease in total courses of antibiotics for chest infections per year) and was favorably received by the patients and their caregivers (78). Most patients in this study were administered combinations of treatment with different concentrations of saline including isotonic or hypertonic saline (3%–7%) and so a dose effect could not be demonstrated. If tolerated, we would initiate treatments with 7% hypertonic saline.
Reversible airflow obstruction
Documentation of an acute response to bronchodilators is not uncommon, and, of course, A-T does not protect a child from also developing asthma. There is no evidence that prescribing inhaled corticosteroids (ICS) to children with A-T and reversible airflow obstruction but no risk factors for asthma, is beneficial. It is suggested that if a trial of ICS is contemplated, it should be for a finite period with definite end-points before the child is committed to long-term therapy. As with any other child, evidence for eosinophilic airway disease should be sought before trialing ICS (Table 3). It should be noted that there is increasing evidence that ICS may increase the risk of airway infection in other contexts, and hence there is a reason for caution in long-term use.
Table 3
| Technique | Comment |
|---|---|
| Raised peripheral blood eosinophil count | Non-specific—can be elevated in other non-asthma atopic disease and parasite infections. |
| Exhaled nitric oxide | Can be collected during tidal breathing even in those who are neurologically impaired Can also be elevated in atopy without asthma. |
| Atopic sensitization (skin prick tests, specific IgE) | Eosinophilic airway inflammation rare in non-atopic children. |
| Eosinophilia of induced or spontaneously expectorated sputum | The gold standard but induced sputum not a routine test. |
Evidence supporting coincident eosinophilic airway inflammation in A-T.
Disordered breathing during sleep
Cardiorespiratory polysomnography (CRPS) should be considered if there is a clinical suspicion of sleep-related breathing abnormalities, rapid or progressive decline in lung function, or if developing scoliosis. As with any child with scoliosis, rapid progression while going through puberty may be seen. If significant sleep-related disordered breathing is confirmed on CRPS, the decision to undertake non-invasive ventilation (NIV) should be made on an individualized basis, based on the benefit outweighing the risk (for example, nocturnal aspiration) and the burden of the treatment.
Interstitial lung disease
Interstitial lung disease in patients with A-T is rare; a definitive diagnosis of ILD was made in 25 out of 97 patients with A-T who had either chronic respiratory symptoms or pulmonary disease listed as a cause of death (out of a total of 437 patients with A-T) (79). The onset of ILD usually occurs in adolescence and is characterized by non-specific symptoms but should be suspected if the child has a persistent dry cough, breathlessness, persistent and especially fine crackles in the absence of respiratory infection, or oxygen desaturation. ILD should be also suspected when pulmonary disease does not respond to antibiotic or bronchodilator treatment (79). A bronchoalveolar lavage and lung biopsy may be helpful in confirming microbiological causes of infections and ILD, respectively (25).
The mortality rate related to ILD in patients with ataxia-telangiectasia is approximately 80%. Aspiration and immunodeficiency do not play a role in the development of ILD, whereas chemotherapeutic drugs such as bleomycin may cause a type of ILD with pulmonary fibrosis dominating (80–82). The histological findings in patients with ataxia-telangiectasia and ILD are unique and do not fit the current classification systems for ILD but could fit in the proposed other known or well-characterized non-genetic or as yet unknown category (83). One should keep in mind that pulmonary involvement of lymphoma may mimic ILD (84).
The evidence base for an investigation pathway is even more scarce but since the treatment is a high dose of oral corticosteroids, most would advocate obtaining a tissue diagnosis before treatment. This would involve a low radiation dose CT scan (ensuring sufficient radiation to acquire adequate images). Other techniques include photon-counting CT which can reduce radiation exposure and reconstruct images at a higher resolution (85), but more evidence its utility in A-T is needed. Imaging should be followed up with video-assisted thoracoscopic surgery (VATS) or an open lung biopsy. Such evidence as exists suggests that early treatment with oral corticosteroids is most beneficial (79) so diagnosis and treatment should be aggressively pursued at an early stage.
Other non-infective respiratory manifestations
Bronchiolitis obliterans has also been described in ataxia-telangiectasia (86). Pleural neoplasms are extremely rare in children, even in patients with A-T, and hence delayed diagnosis of conditions such as malignant pleural mesothelioma can occur in these patients (87). Parenchymal lung involvement is not uncommon in Hodgkin's disease, one of the well-described hematological malignancies in A-T; however, pulmonary infiltration with cavitation in the lung parenchyma is quite unusual and can be associated with a fatal outcome (84).
Planning for surgical procedures
The term ataxia-telangiectasia cannot be found in a British Thoracic Society comprehensive document (
88) on respiratory management of children with neuromuscular weakness, highlighting the lack of evidence in managing this rare disorder. Surgery (for gastrostomy insertion or scoliosis) in children with A-T should take place in units with experienced pediatric surgeons, anesthetists, and physiotherapists, and where there are facilities for pediatric intensive care and NIV. These children should be assessed by a multidisciplinary team prior to any intervention. Anesthesia carries risks for these patients comparable to other medically complex patients. Precautions include a full evaluation of the following potentially impaired bodily systems prior to anesthesia:
- •
Neurological—in particular assessing cerebellar and bulbar function, minimizing the risk of aspiration during the induction of anesthesia.
- •
Respiratory—seeking and treating infection, undertaking a sleep study, and considering whether the child might need NIV postoperatively, and if so, familiarize themselves with it preoperatively.
- •
Cardiovascular evaluation to be aware of the potential effects of increased pulmonary vascular resistance, which may be a complication of chronic lung disease.
- •
Hematological—looking for malignancies resulting in pancytopenia and necessitating transfusion of blood and platelets preoperatively.
- •
Metabolic—diabetes has been found to be present in 18% of patients with A-T after puberty (89) and would require careful perioperative management.
- •
Optimize nutrition.
Early reports suggested high perioperative morbidity in A-T (
75), while the results of the largest published series are more favorable, reporting that general anesthesia, airway manipulation, and perioperative mechanical ventilation may be tolerated with only minor postoperative anesthetic concerns (
90) even when anesthesia was required for the surgical management of recurrent infective pleural effusions (
91). Effective airway clearance techniques, and early or even immediate use of NIV following extubation should be anticipated and planned. The outcomes of invasive ventilation are less good with case reports of adverse outcomes (
92). Given the likelihood of amplified damage from oxidative stress due to the abnormal DNA damage response (
4), the recent suggestion of a conservative oxygenation saturation target (SpO
288%–92%) could be very relevant if a child with A-T was admitted and invasively ventilated (
93).
Growth and nutrition
Undernutrition adversely affects lung health. Poor nutritional status and decreased pulmonary function have been shown to be linked in other diseases, including CF. Worsening nutritional status increases infection-related morbidity and mortality. Malnutrition is of particular concern in children since it adversely affects the normal accrual of height and weight and may impact lung development.
Several studies have shown that patients with A-T exhibit high rates of malnutrition, short stature, and reduced lean body mass (94–101). Worsening nutritional status over time in CYP with A-T can be progressive in a third to half of patients (99, 101).
Early gastrostomy insertion stabilizes nutrition decline, improves growth, minimizes the risk of aspiration, is better tolerated, and improves the quality of life of CYP with A-T and that of their caregivers (99, 102).
Swallowing/aspiration assessment
Aspiration occurs in many patients, especially in those who are older and malnourished (104).
Table 4
| Oral-motor clinical assessment | Lip closure |
| Tongue movement | |
| Palatal elevation | |
| Gag reflex | |
| Voice quality | |
| Speech motor control | |
| Clinical swallowing assessment using a multidimensional tool designed to measure both the supervision level required and the diet level |
|
| |
| |
| |
| |
| |
| |
| Penetration/aspiration assessment (103) |
|
| |
| |
| |
| |
| |
| |
|
A penetration–aspiration scale for assessment of swallowing and aspiration (103).
Early detection and treatment of swallowing dysfunction appear to decrease morbidity associated with dysphagia and enable early oral rehabilitation (i.e., compensatory strategies and diet modification), which in turn could decrease the risk of aspiration pneumonia and improve the quality of life of affected individuals. The standard means of swallowing assessment with a videofluoroscopic swallow study (VFSS) are limited by concerns about radiation exposure and a cumulative dose of radiation exposure that may result from multiple studies, especially in a condition such as A-T with increased radiation sensitivity (104).
Swallowing and aspiration-related problems become more prevalent as the neurological difficulties progress. Symptoms of unsafe swallowing include coughing and choking during meals, incoordination between breathing and swallowing events, absence of the cough reflex, change in voice quality (hoarse, wet/crackly, or weak voice), and difficulty in maintaining weight or loss of weight. A review by an experienced speech and language therapist should include an oral-motor assessment and a clinical swallowing assessment, preferably using a scale that describes penetration and aspiration (Table 4) (103). Low-dose, modified VFSS may be used in exceptional cases (104, 105); however, a clinical assessment that avoids the use of ionizing radiation would be preferable. The use of cervical auscultation of swallowing and respiratory sounds and/or vibrations has been shown to have a high sensitivity and specificity in the detection of oropharyngeal aspiration (106). Other methods that do not require the use of ionizing radiation include fiberoptic endoscopic evaluation of swallowing (FEES) (106) or videostroboscopy (107) to provide improved dynamic visualization of the glottis. However, both these methods require special expertise and equipment and data in A-T are lacking.
More advanced methods of assessment such as using a respirodeglutometer (RDG DFI Enterprises, Inc., Morrisville, NY, USA) provide valuable insight into the physiological basis of respiration–swallowing coordination. However, this is not used in routine clinical care, and, at present, is primarily a research technique. These recordings provide non-invasive measures of respiratory airflow during swallowing. Assessment may allow initiation of treatment before the development of sequelae in persons at increased risk for the development of aspiration. An expiration–swallow–expiration (E–Sw–E) pattern of peri-deglutitive airflow is considered the safest pattern of coupling for swallowing; inspiration-swallow-inspiration (I-Sw-I), the least safe pattern. Regardless of age, E–Sw–E was the most common pattern for both patients with ataxia-telangiectasia and healthy participants. In a small study in a specialized A-T center, patients with A-T were shown to have proportionately fewer E–Sw–E airflow patterns than their age-matched healthy controls; they generated more frequent inspiratory airflow patterns either before deglutition, after deglutition, or both. Furthermore, the least safe pattern, I–Sw–I, occurred significantly more often in older patients with A-T than in the controls (108).
Early expert input from a speech and language therapist to implement changes in feeding routine such as elimination of thin liquids, pacing to slow the rate of liquid intake, and having easily chewable food, among others, is valuable. Advice about body posture to maintain an upright stable position to avoid shortening of the neck during eating and drinking is crucial (25).
What is on the horizon?
It is beyond the remit of this review to discuss future research in detail. We will very briefly highlight some of the current ongoing research that may have disease-modifying potential in the future.
- •
Genetic modification: A study on the use of personalized antisense oligonucleotides (ASOs) in a 3-year-old girl with A-T is still ongoing and may become a promising disease-modifying treatment (109). The large size of the ATM protein has so far eluded viral vector-based gene therapy, which has shown some promise in spinal muscular atrophy (110) and Tay–Sachs disease (111).
- •
Stem cell/bone marrow transplant: Pre-emptive allogeneic hematopoietic stem cell transplant (alloHSCT) led to the correction of immunodeficiency in a 4-year-old boy with A-T. An acceptable risk of transplant-related mortality was reported in this case report (112). However, the risks of life-threatening events associated with the drugs and radiation used for pre-transplant preparative regimens are not insignificant (113)
- •
A recent review (114) has summarized some other treatment approaches that target oxidative stress and inflammation. Experimental work has shown the potential for triheptanoin, a synthetic medium-chain triglyceride (115), to correct metabolic stress in A-T cells.
Summary
We have provided an overview of respiratory morbidity in this ultrarare disease. There are multiple contributors to respiratory disease in A-T and respiratory disease is the leading cause of death in patients with A-T along with cancer. Regular proactive measures are recommended to detect and manage lung disease in patients with A-T in an attempt to modify the impact of this devastating condition and an unpublished work (personal communication) suggests that more young people with A-T are being transitioned to adult A-T clinics with this proactive approach.
Statements
Author contributions
JMB: Writing – original draft, Writing – review & editing, Conceptualization, Methodology, Project administration. AB: Writing – review & editing, Conceptualization, Methodology.
Funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
SwiftMMorrellDCromartieEChamberlinARSkolnickMHBishopDT. The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet. (1986) 39(5):573–83.
2.
Orphanet: Ataxia-telangiectasia. Available online at:https://www.orpha.net/en/disease/detail/100?name=Ataxia-telangiectasia&mode=name) (cited July 25, 2024).
3.
WoodsCGBundeySETaylorAM. Unusual features in the inheritance of ataxia telangiectasia. Hum Genet. (1990) 84(6):555–62. 10.1007/BF00210809
4.
HuffLAYanSClemensMG. Mechanisms of ataxia telangiectasia mutated (ATM) control in the DNA damage response to oxidative stress, epigenetic regulation, and persistent innate immune suppression following sepsis. Antioxid Basel Switz. (2021) 10(7):1146. 10.3390/antiox10071146
5.
McGrath-MorrowSARothblum-OviattCCWrightJSchlechterHLefton-GreifMANataleVAet alMultidisciplinary management of ataxia telangiectasia: current perspectives. J Multidiscip Healthc. (2021) 14:1637–44. 10.2147/JMDH.S295486
6.
WeiteringTJTakadaSWeemaesCMRvan SchouwenburgPAvan der BurgM. ATM: translating the DNA damage response to adaptive immunity. Trends Immunol. (2021) 42(4):350–65. 10.1016/j.it.2021.02.001
7.
de VillartayJP. Congenital defects in V(D)J recombination. Br Med Bull. (2015) 114(1):157–67. 10.1093/bmb/ldv020
8.
StaplesERMcDermottEMReimanAByrdPJRitchieSTaylorAMRet alImmunodeficiency in ataxia telangiectasia is correlated strongly with the presence of two null mutations in the ataxia telangiectasia mutated gene. Clin Exp Immunol. (2008) 153(2):214–20. 10.1111/j.1365-2249.2008.03684.x
9.
VerhagenMMMLastJIHogervorstFBLSmeetsDFCMRoeleveldNVerheijenFet alPresence of ATM protein and residual kinase activity correlates with the phenotype in ataxia-telangiectasia: a genotype-phenotype study. Hum Mutat. (2012) 33(3):561–71. 10.1002/humu.22016
10.
van OsNJHJansenAFMvan DeurenMHaraldssonAvan DrielNTMEtzioniAet alAtaxia-telangiectasia: immunodeficiency and survival. Clin Immunol. (2017) 178:45–55. 10.1016/j.clim.2017.01.009
11.
AghamohammadiAImaiKMoazzamiKAbolhassaniHTabatabaeiyanMParvanehNet alAtaxia-telangiectasia in a patient presenting with hyper-immunoglobulin M syndrome. J Investig Allergol Clin Immunol. (2010) 20(5):442–5.
12.
AzarsizEKaracaNEGunaydinNCGulezNOzturkCAksuGet alDo elevated serum IgM levels have to be included in probable diagnosis criteria of patients with ataxia-telangiectasia?Int J Immunopathol Pharmacol. (2014) 27(3):421–7. 10.1177/039463201402700312
13.
NoordzijJGWulffraatNMHaraldssonAMeytsIVeerLvHogervorstFBLet alAtaxia-telangiectasia patients presenting with hyper-IgM syndrome. Arch Dis Child. (2009) 94(6):448–9. 10.1136/adc.2008.149351
14.
RawatAImaiKSuriDGuptaABhisikarSSaikiaBet alAtaxia telangiectasia masquerading as hyper IgM syndrome. Indian J Pediatr. (2016) 83(3):270–1. 10.1007/s12098-015-1852-x
15.
TangsinmankongNWayneASHowenstineMSWashingtonKRLangstonCGattiRAet alLymphocytic interstitial pneumonitis, elevated IgM concentration, and hepatosplenomegaly in ataxia-telangiectasia. J Pediatr. (2001) 138(6):939–41. 10.1067/mpd.2001.113356
16.
KrauthammerALahadAGoldbergLSaroukIWeissBSomechRet alElevated IgM levels as a marker for a unique phenotype in patients with Ataxia telangiectasia. BMC Pediatr. (2018) 18(1):185. 10.1186/s12887-018-1156-1
17.
Szczawińska-PopłonykATąpolska-JóźwiakKSchwartzmannEPietruchaB. Infections and immune dysregulation in ataxia-telangiectasia children with hyper-IgM and non-hyper-IgM phenotypes: a single-center experience. Front Pediatr. (2022) 10:972952. 10.3389/fped.2022.972952
18.
TakadaSWeiteringTJvan OsNJHDuLPico-KnijnenburgIKuipersTBet alCausative mechanisms and clinical impact of immunoglobulin deficiencies in ataxia telangiectasia. J Allergy Clin Immunol. (2024) 153(5):1392–405. 10.1016/j.jaci.2023.12.029
19.
Nowak-WegrzynACrawfordTOWinkelsteinJACarsonKALedermanHM. Immunodeficiency and infections in ataxia-telangiectasia. J Pediatr. (2004) 144(4):505–11. 10.1016/j.jpeds.2003.12.046
20.
BottLLebretonJThumerelleCCuvellierJDeschildreASardetA. Lung disease in ataxia-telangiectasia: ataxia-telangiectasia. Acta Paediatr. (2007) 96(7):1021–4. 10.1111/j.1651-2227.2007.00338.x
21.
SchroederSAZielenS. Infections of the respiratory system in patients with ataxia-telangiectasia: pulmonary disease in patients with Ataxia-telangiectasia clean R3. Pediatr Pulmonol. (2014) 49(4):389–99. 10.1002/ppul.22817
22.
BhattJMBushA. Microbiological surveillance in lung disease in ataxia telangiectasia. Eur Respir J. (2014) 43(6):1797–801. 10.1183/09031936.00141413
23.
Blanchard-RohnerGPeiroloACoulonLKorffCHorvathJBurkhardPRet alChildhood-onset movement disorders can mask a primary immunodeficiency: 6 cases of classical Ataxia-telangiectasia and variant forms. Front Immunol. (2022) 13:791522. 10.3389/fimmu.2022.791522
24.
van OsNJHHaaxmaCAvan der FlierMMerkusPJFMvan DeurenMde GrootIJMet alAtaxia-telangiectasia: recommendations for multidisciplinary treatment. Dev Med Child Neurol. (2017) 59(7):680–9. 10.1111/dmcn.13424
25.
BhattJMBushAvan GervenMNissenkornARenkeMYarlettLet alERS Statement on the multidisciplinary respiratory management of ataxia telangiectasia. Eur Respir Rev. (2015) 24(138):565–81. 10.1183/16000617.0066-2015
26.
CrawfordTOMandirASLefton-GreifMAGoodmanSNGoodmanBKSengulHet alQuantitative neurologic assessment of Ataxia-telangiectasia. Neurology. (2000) 54(7):1505–9. 10.1212/WNL.54.7.1505
27.
CrawfordTO. Survival probability in ataxia telangiectasia. Arch Dis Child. (2005) 91(7):610–1. 10.1136/adc.2006.094268
28.
DevaneyRPasalodosSSuriMBushABhattJM. Ataxia telangiectasia: presentation and diagnostic delay. Arch Dis Child. (2017) 102(4):328–30. 10.1136/archdischild-2016-310477
29.
PetleyEYuleAAlexanderSOjhaSWhitehouseWP. The natural history of ataxia-telangiectasia (A-T): a systematic review. Chen TH, editor. PLoS One. (2022) 17(3):e0264177. 10.1371/journal.pone.0264177
30.
DoshiARyuJThornburgCDHersheyDCherryRMilliganKet alAtaxia telangiectasia presenting as hyper IgM syndrome without neurologic signs. Ann Allergy Asthma Immunol. (2016) 117(3):221–6. 10.1016/j.anai.2016.07.028
31.
AndrewsBFKopackFMBrutonOC. A syndrome of ataxia, oculocutaneous telangiectasia, and sinopulmonary infections. U S Armed Forces Med J. (1960) 11:587–92.
32.
SakIKızılırmakDHavlucuYYılmazZÇelikP. The investigated case of etiology of chylous pleural effusion: ataxia-telangiectasia. Tuberk Ve Toraks. (2022) 70(1):102–6. 10.5578/tt.20229912
33.
KeklikMKokerMYSivginSCamlicaDPalaCCetinMet alDetection of acute lymphoblastic leukemia involvement in pleural fluid in an adult patient with ataxia telangiectasia by flow cytometry method. Indian J Hematol Blood Transfus. (2014) 30(S1):73–6. 10.1007/s12288-013-0253-4
34.
ÖzyörükDGüzelküçükZHacisalihogluŞCinelG. The development of chylothorax in a child with T-cell lymphoblastic lymphoma and ataxia telangiectasia during induction therapy. J Pediatr Hematol Oncol. (2022) 44(2):e554–6. 10.1097/MPH.0000000000002039
35.
ChuangSDoumitMMcDonaldRHennessyEKatzTJaffeA. Annual review clinic improves care in children with cystic fibrosis. J Cyst Fibros. (2014) 13(2):186–9. 10.1016/j.jcf.2013.09.001
36.
BurgelPRSouthernKWAddyCBattezzatiABerryCBoucharaJPet alStandards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues. J Cyst Fibros. (2024) 23(2):187–202. 10.1016/j.jcf.2024.01.005
37.
McGrath-MorrowSLefton-GreifMRosquistKCrawfordTKellyAZeitlinPet alPulmonary function in adolescents with ataxia telangiectasia. Pediatr Pulmonol. (2008) 43(1):59–66. 10.1002/ppul.20738
38.
McGrath-MorrowSA. Pulmonary function in children and young adults with ataxia telangiectasia: PFTs in children and young adults with A-T. Pediatr Pulmonol. (2014) 49(1):84–990. 10.1002/ppul.22760
39.
VilozniDBerkunYLeviYWeissBJacobsonJMEfratiO. The feasibility and validity of forced spirometry in ataxia telangiectasia. Pediatr Pulmonol. (2010) 45(10):1030–6. 10.1002/ppul.21291
40.
TanJPrayleASpencerSMcNarryNAndrewBBhattJM. Sniff nasal inspiratory pressure and peak cough flow in children with ataxia telangiectasia. Eur Respir J. (2016) 48(suppl 60):374. Available online at:https://erj.ersjournals.com/content/48/suppl_60/PA374.abstract
41.
PerremLGaiettoKWeinerDJRosenfeldM. Advances in pediatric lung function testing techniques. Clin Chest Med. (2024) 45(3):543–53. 10.1016/j.ccm.2024.03.003
42.
BednarekMGrabickiMPiorunekTBatura-GabryelH. Current place of impulse oscillometry in the assessment of pulmonary diseases. Respir Med. (2020) 170:105952. 10.1016/j.rmed.2020.105952
43.
MarczakHPeradzyńskaJLangeJBogusławskiSKrenkeK. Pulmonary function in children with persistent tachypnea of infancy. Pediatr Pulmonol. (2023) 58(1):81–7. 10.1002/ppul.26162
44.
de AlegriaSGLitrentoPFde Oliveira FariasIMafortTTLopesAJ. Can home rehabilitation impact impulse oscillometry and lung ultrasound findings in patients with scleroderma-associated interstitial lung disease? A pilot study. BMC Res Notes. (2022) 15(1):176. 10.1186/s13104-022-06064-6
45.
ChengWCChangSHChenWCWuBRChenCHLinCCet alApplication of impulse oscillometry to detect interstitial lung disease and airway disease in adults with rheumatoid arthritis. BMC Pulm Med. (2023) 23(1):331. 10.1186/s12890-023-02615-0
46.
KingGGBatesJBergerKICalverleyPDe MeloPLDellacàRLet alTechnical standards for respiratory oscillometry. Eur Respir J. (2020) 55(2):1900753. 10.1183/13993003.00753-2019
47.
BusackLMTheeSLiuYAllombaCZiegahnNTosoliniAet alMultiple-breath washout to detect lung disease in patients with inborn errors of immunity. ERJ Open Res. (2024) 10(2):01019–2023. 10.1183/23120541.01019-2023
48.
McGrath-MorrowSACollacoJMDetrickBLedermanHM. Serum interleukin-6 levels and pulmonary function in ataxia-telangiectasia. J Pediatr. (2016) 171:256–61.e1. 10.1016/j.jpeds.2016.01.002
49.
McGrath-MorrowSANdehRCollacoJMRothblum-OviattCWrightJO'ReillyMAet alInflammation and transcriptional responses of peripheral blood mononuclear cells in classic ataxia telangiectasia. PLoS One. (2018) 13(12):e0209496. 10.1371/journal.pone.0209496
50.
WeerasingheDPBurtonLChiccoPPearsonMMackeyDJFalkGL. Acute oxygen desaturation characterizes pulmonary aspiration in patients with gastroesophageal reflux disease and laryngopharyngeal reflux. Physiol Rep. (2022) 10(12):e15367. 10.14814/phy2.15367
51.
Jończyk-PotocznaKPotocznyJSzczawińska-PopłonykA. Imaging in children with ataxia-telangiectasia-the radiologist’s approach. Front Pediatr. (2022) 10:988645. 10.3389/fped.2022.988645
52.
MontellaSMollicaCFinocchiAPessionAPietrograndeMCTrizzinoAet alNon invasive assessment of lung disease in ataxia telangiectasia by high-field magnetic resonance imaging. J Clin Immunol. (2013) 33(7):1185–91. 10.1007/s10875-013-9933-y
53.
LonzettiLZanonMPaciniGSAltmayerSde OliveiraDMRubinASet alMagnetic resonance imaging of interstitial lung diseases: a state-of-the-art review. Respir Med. (2019) 155:79–85. 10.1016/j.rmed.2019.07.006
54.
PrayleATibilettiMYouleCSafaviSAlenaziSPaulJAet alEarly experience of oxygen enhanced magnetic resonance imaging (OE-MRI) in ataxia telangiectasia (A-T). Eur Respir J. (2018) 52(suppl 62):3888. Available online at:https://erj.ersjournals.com/content/52/suppl_62/PA3888.abstract
55.
AyméS. State of the art of rare disease activities in Europe: a EUCERD perspective. Orphanet J Rare Dis. (2012) 7(Suppl 2):A1. 10.1186/1750-1172-7-S2-A1
56.
DaviesEG. Update on the management of the immunodeficiency in ataxia-telangiectasia. Expert Rev Clin Immunol. (2009) 5(5):565–75. 10.1586/eci.09.35
57.
WarrenRDylagAMBehanMDommWYeeMMayer-PröschelMet alAtaxia telangiectasia mutated is required for efficient proximal airway epithelial cell regeneration following influenza a virus infection. Am J Physiol Lung Cell Mol Physiol. (2022) 322(4):L581–92. 10.1152/ajplung.00378.2021
58.
AbolhassaniHVosughimotlaghAAsanoTLandegrenNBoissonBDelavariSet alX-linked TLR7 deficiency underlies critical COVID-19 pneumonia in a male patient with ataxia-telangiectasia. J Clin Immunol. (2022) 42(1):1–9. 10.1007/s10875-021-01151-y
59.
GrayDMDaviesMAGithinjiLLevinMMapaniMNowalazaZet alCOVID-19 and pediatric lung disease: a South African tertiary center experience. Front Pediatr. (2021) 8:614076. 10.3389/fped.2020.614076
60.
MoellerAThanikkelLDuijtsLGaillardEAGarcia-MarcosLKantarAet alCOVID-19 in children with underlying chronic respiratory diseases: survey results from 174 centres. ERJ Open Res. (2020) 6(4):00409–2020. 10.1183/23120541.00409-2020
61.
A-T-and-COVID-19-Vaccines. Available online at:https://www.atcp.org/wp-content/uploads/2021/01/A-T-and-COVID-19-Vaccines.pdf#:∼:text=None%20of%20e%20COVID-19%20vaccines%20contains%20live%20virus;%20erefore,%20ey(Accessed October 01, 2024).
62.
COVID-19—SARS-CoV-2. Available online at:https://assets.publishing.service.gov.uk/media/66e7fbf624c4f1826d81bb32/Greenbook-chapter-14a-20240916.pdf(Accessed October 01, 2024).
63.
MicolRBen SlamaLSuarezFLe MignotLBeautéJMahlaouiNet alMorbidity and mortality from ataxia-telangiectasia are associated with ATM genotype. J Allergy Clin Immunol. (2011) 128(2):382–9.e1. 10.1016/j.jaci.2011.03.052
64.
YeoAJHenninghamAFantinoEGalbraithSKrauseLWainwrightCEet alIncreased susceptibility of airway epithelial cells from ataxia-telangiectasia to S. pneumoniae infection due to oxidative damage and impaired innate immunity. Sci Rep. (2019) 9(1):2627. 10.1038/s41598-019-38901-3
65.
Méndez-EchevarríaACaminoaMBDel RosalTCasasIPozoFPascual-PascualSIet alThe role of respiratory viruses in children with ataxia-telangiectasia. Viruses. (2021) 13(5):867. 10.3390/v13050867
66.
PonsfordMJPriceCFarewellDGreeneGMooreCPerryMet alIncreased respiratory viral detection and symptom burden among patients with primary antibody deficiency: results from the BIPAD study. J Allergy Clin Immunol Pract. (2021) 9(2):735–744.e6. 10.1016/j.jaip.2020.08.016
67.
BreuerOCaudriDAkessonLRanganathanSStickSMSchultzAet alThe clinical significance of oropharyngeal cultures in young children with cystic fibrosis. Eur Respir J. (2018) 51(5):1800238. 10.1183/13993003.00238-2018
68.
RonchettiKTameJDPaiseyCThiaLPDoullIHoweRet alThe CF-Sputum Induction Trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial. Lancet Respir Med. (2018) 6(6):461–71. 10.1016/S2213-2600(18)30171-1
69.
Langton HewerSCSmithSRowbothamNJYuleASmythAR. Antibiotic strategies for eradicating pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. (2023) 6(6):CD004197. 10.1002/14651858.CD004197.pub6
70.
MilitoCPulvirentiFCinettoFLougarisVSoresinaAPecoraroAet alDouble-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies. J Allergy Clin Immunol. (2019) 144(2):584–93.e7. 10.1016/j.jaci.2019.01.051
71.
DriessenGJIJspeertHWeemaesCMRHaraldssonÁTripMWarrisAet alAntibody deficiency in patients with ataxia telangiectasia is caused by disturbed B- and T-cell homeostasis and reduced immune repertoire diversity. J Allergy Clin Immunol. (2013) 131(5):1367–75.e9. 10.1016/j.jaci.2013.01.053
72.
GudisDACohenNA. Cilia dysfunction. Otolaryngol Clin North Am. (2010) 43(3):461–72, vii. 10.1016/j.otc.2010.02.007
73.
FélixEGimenesACCosta-CarvalhoBT. Effects of inspiratory muscle training on lung volumes, respiratory muscle strength, and quality of life in patients with ataxia telangiectasia: inspiratory training in ataxia telangiectasia. Pediatr Pulmonol. (2014) 49(3):238–44. 10.1002/ppul.22828
74.
Ataxia-telangiectasia in children Guidance on diagnosis and clinical care. Available online at:http://www.atsociety.org.uk/data/files/William/A-T_Clinical_Guidance_Document_Final.pdf(Cited March 17, 2015).
75.
VeenhuisSvan OsNWeemaesCKamsteegE-JWillemsenM. Ataxia-Telangiectasia. In: AdamMPFeldmanJMirzaaGMPagonRAWallaceSEAmemiyaA, editors. GeneReviews®. Seattle, WA: University of Washington, Seattle (1999). Available online at:https://www.ncbi.nlm.nih.gov/books/NBK26468/(cited March 2015).
76.
Rothblum-OviattCWrightJLefton-GreifMAMcGrath-MorrowSACrawfordTOLedermanHM. Ataxia telangiectasia: a review. Orphanet J Rare Dis. (2016) 11(1):159. 10.1186/s13023-016-0543-7
77.
KhanMCassidyEParkinTWallaceACarterBPatonJet alThe care and management of children and young people with ataxia telangiectasia provided by nurses and allied health professionals: a scoping review. Cerebellum. (2023) 23(2):722–56. 10.1007/s12311-023-01555-z
78.
Galaz SouzaNBushATanHL. Exploratory study of the effectiveness of nebulised saline in children with neurodisability. Eur Respir J. (2021) 57(3):2001407. 10.1183/13993003.01407-2020
79.
SchroederSASwiftMSandovalCLangstonC. Interstitial lung disease in patients with ataxia-telangiectasia. Pediatr Pulmonol. (2005) 39(6):537–43. 10.1002/ppul.20209
80.
ChenRLWangPJHsuYHChangPYFangJS. Severe lung fibrosis after chemotherapy in a child with ataxia-telangiectasia. J Pediatr Hematol Oncol. (2002) 24(1):77–9. 10.1097/00043426-200201000-00021
81.
SandovalCSwiftM. Treatment of lymphoid malignancies in patients with ataxia-telangiectasia. Med Pediatr Oncol. (1998) 31(6):491–7. 10.1002/(SICI)1096-911X(199812)31:6%3C491::AID-MPO5%3E3.0.CO;2-B
82.
SandovalCSwiftM. Hodgkin disease in ataxia-telangiectasia patients with poor outcomes. Med Pediatr Oncol. (2003) 40(3):162–6. 10.1002/mpo.10251
83.
BushANogeeL. Children’s interstitial lung disease (chILD): less rare than we thought?Thorax. (2024) 79(9):807–8. 10.1136/thorax-2024-221951
84.
YalçinBKutlukMTSanalOAkyüzCAnadolDCağlarMet alHodgkin’s disease and ataxia telangiectasia with pulmonary cavities. Pediatr Pulmonol. (2002) 33(5):399–403. 10.1002/ppul.10057
85.
WilleminkMJPerssonMPourmortezaAPelcNJFleischmannD. Photon-counting CT: technical principles and clinical prospects. Radiology. (2018) 289(2):293–312. 10.1148/radiol.2018172656
86.
ItoMNakagawaAHirabayashiNAsaiJ. Bronchiolitis obliterans in ataxia-telangiectasia. Virchows Arch Int J Pathol. (1997) 430(2):131–7. 10.1007/BF01008034
87.
Rosas-SalazarCGunawardenaSWSpahrJE. Malignant pleural mesothelioma in a child with ataxia-telangiectasia. Pediatr Pulmonol. (2013) 48(1):94–7. 10.1002/ppul.22535
88.
HullJAniapravanRChanEChatwinMFortonJGallagherJet alBritish thoracic society guideline for respiratory management of children with neuromuscular weakness. Thorax. (2012) 67(Suppl 1):i1–40. 10.1136/thoraxjnl-2012-201964
89.
DonathHHessUKieslichMTheisMOhlenschlägerUSchubertRet alDiabetes in patients with ataxia telangiectasia: a national cohort study. Front Pediatr. (2020) 8:317. 10.3389/fped.2020.00317
90.
LockmanJLIskanderAJBembeaMCrawfordTOLedermanHMMcGrath-MorrowSet alAnesthetic and perioperative risk in the patient with ataxia-telangiectasia. Paediatr Anaesth. (2012) 22(3):256–62. 10.1111/j.1460-9592.2011.03739.x
91.
Jovanovski-SrcevaMKondovGKartalovAGeorgievAKuzmanovskiIOsmaniBet alAnesthetic chalenges and managment in patient with ataxia- telangiectasia. Pril (Makedon Akad Nauk Umet Odd Med Nauki). (2023) 44(3):65–71. 10.2478/prilozi-2023-0048
92.
VerhagenMMMvan DeurenMWillemsenMAAPVan der HoevenHJHeijdraYFYntemaJBet alAtaxia-Telangiectasia and mechanical ventilation: a word of caution. Pediatr Pulmonol. (2009) 44(1):101–2. 10.1002/ppul.20957
93.
PetersMJGouldDWRaySThomasKChangIOrzolMet alOxy-PICU investigators of the paediatric critical care society study group (PCCS-SG). conservative versus liberal oxygenation targets in critically ill children (Oxy-PICU): a UK multicentre, open, parallel-group, randomised clinical trial. Lancet Lond Engl. (2024) 403(10424):355–64. 10.1016/S0140-6736(23)01968-2
94.
SchubertRReichenbachJZielenS. Growth factor deficiency in patients with ataxia telangiectasia. Clin Exp Immunol. (2005) 140(3):517–9. 10.1111/j.1365-2249.2005.02782.x
95.
da SilvaRdos Santos-ValenteECBurim ScompariniFSaccardo SarniROCosta-CarvalhoBT. The relationship between nutritional status, vitamin A and zinc levels and oxidative stress in patients with ataxia-telangiectasia. Allergol Immunopathol. (2014) 42(4):329–35. 10.1016/j.aller.2013.02.013
96.
VossSPietznerJHocheFTaylorAMRLastJISchubertRet alGrowth retardation and growth hormone deficiency in patients with ataxia telangiectasia. Growth Factors. (2014) 32(3–4):123–9. 10.3109/08977194.2014.939805
97.
EhlayelMSolimanADe SanctisV. Linear growth and endocrine function in children with ataxia telangiectasia. Indian J Endocrinol Metab. (2014) 18(Suppl 1):S93–6. 10.4103/2230-8210.145079
98.
RossLJCapraSBaguleyBSinclairKMunroKLewindonPet alNutritional status of patients with ataxia-telangiectasia: a case for early and ongoing nutrition support and intervention. J Paediatr Child Health. (2015) 51(8):802–7. 10.1111/jpc.12828
99.
StewartEPrayleAPTookeAPasalodosSSuriMBushAet alGrowth and nutrition in children with ataxia telangiectasia. Arch Dis Child. (2016) 101(12):1137–41. 10.1136/archdischild-2015-310373
100.
KrauthammerALahadASaroukYSomechRNissenkornAModan-MosesDet alLong-term nutritional and gastrointestinal aspects in patients with ataxia telangiectasia. Nutrition. (2018) 46:48–52. 10.1016/j.nut.2017.08.008
101.
NataleVAIColeTJRothblum-OviattCWrightJCrawfordTOLefton-GreifMAet alGrowth in ataxia telangiectasia. Orphanet J Rare Dis. (2021) 16(1):123. 10.1186/s13023-021-01716-5
102.
Lefton-GreifMACrawfordTOMcGrath-MorrowSCarsonKALedermanHM. Safety and caregiver satisfaction with gastrostomy in patients with ataxia telangiectasia. Orphanet J Rare Dis. (2011) 6:23. 10.1186/1750-1172-6-23
103.
RosenbekJCRobbinsJARoeckerEBCoyleJLWoodJL. A penetration-aspiration scale. Dysphagia. (1996) 11(2):93–8. 10.1007/BF00417897
104.
Lefton-GreifMACrawfordTOWinkelsteinJALoughlinGMKoernerCBZahurakMet alOropharyngeal dysphagia and aspiration in patients with ataxia-telangiectasia. J Pediatr. (2000) 136(2):225–31. 10.1016/S0022-3476(00)70106-5
105.
Rondon-MeloSde AlmeidaIJAndradeCdSassiFCMolini-AvejonasDR. Ataxia telangiectasia in siblings: oral motor and swallowing characterization. Am J Case Rep. (2017) 18:783–9. 10.12659/AJCR.903592
106.
CronACDavidMOrbell-SmithJChangABWeirKAFrakkingTT. Cervical auscultation for detecting oropharyngeal aspiration in paediatric and adult populations: a systematic review and meta-analysis. Clin Otolaryngol. (2024) 49(6):713–24. 10.1111/coa.14202
107.
RajaeiABarzegar BafrooeiEMojiriFNilforoushMH. The occurrence of laryngeal penetration and aspiration in patients with glottal closure insufficiency. ISRN Otolaryngol. (2014) 2014:587945. 10.1155/2014/587945
108.
Lefton-GreifMAPerlmanALHeXLedermanHMCrawfordTO. Assessment of impaired coordination between respiration and deglutition in children and young adults with ataxia telangiectasia. Dev Med Child Neurol. (2016) 58(10):1069–75. 10.1111/dmcn.13156
109.
CornelissenLDonadoCYuTWBerdeCB. Modified sensory testing in non-verbal patients receiving novel intrathecal therapies for neurological disorders. Front Neurol. (2022) 13:664710. 10.3389/fneur.2022.664710
110.
KirschnerJBernertGButoianuNDe WaeleLFattal-ValevskiAHaberlovaJet al2024 update: European consensus statement on gene therapy for spinal muscular atrophy. Eur J Paediatr Neurol. (2024) 51:73–8. 10.1016/j.ejpn.2024.06.001
111.
FlotteTRCataltepeOPuriABatistaARMoserRMcKenna-YasekDet alAAV Gene therapy for Tay-Sachs disease. Nat Med. (2022) 28(2):251–9. 10.1038/s41591-021-01664-4
112.
DueckerRBaerPCBueckerAHueneckeSPfeffermannLMModlichUet alHematopoietic stem cell transplantation restores naïve T-cell populations in Atm-deficient mice and in preemptively treated patients with ataxia-telangiectasia. Front Immunol. (2019) 10:2785. 10.3389/fimmu.2019.02785
113.
UpadhyayaSAModyRWalkovichKHutchinsonRJSandlundJTConnellyJA. Ataxia telangiectasia and cancer predisposition: challenges in management. J Pediatr Hematol Oncol. (2018) 40(6):483–6. 10.1097/MPH.0000000000001005
114.
KuhnKLedermanHMMcGrath-MorrowSA. Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome. Expert Opin Investig Drugs. (2023) 32(8):693–704. 10.1080/13543784.2023.2249399
115.
YeoAJSubramanianGNChongKLGateiMPartonRGComanDet alAn anaplerotic approach to correct the mitochondrial dysfunction in ataxia-telangiectasia (A-T). Mol Metab. (2021) 54:101354. 10.1016/j.molmet.2021.101354
Summary
Keywords
Ataxia-telangiectasia, lung disease, bronchiectasis, aspiration, interstitial lung disease
Citation
Bhatt JM and Bush A (2024) An overview of proactive monitoring and management of respiratory issues in ataxia-telangiectasia in a specialist and shared care pediatric clinic. Front. Pediatr. 12:1479620. doi: 10.3389/fped.2024.1479620
Received
12 August 2024
Accepted
27 November 2024
Published
23 December 2024
Volume
12 - 2024
Edited by
Mark Lloyd Everard, University of Western Australia, Australia
Reviewed by
Jackson Y. W. Wong, Peak Pulmonary Specialty Clinic, Canada
Andre Schultz, Perth Children’s Hospital, Australia
Updates
Copyright
© 2024 Bhatt and Bush.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jayesh Mahendra Bhatt jayesh.bhatt@nhs.net
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.